APTXNasdaqinactive

Aptinyx Inc.

Healthcare·Oncology·Commercial
OncologyNeurologyImmunologyOphthalmologyCardiovascularInfectious DiseaseMetabolicRespiratoryPainDermatologyNephrologyMusculoskeletal

Aptinyx Inc. (APTX): 27 pipeline candidates · ~12 mo cash runway. Updated within the last hour.

7.8/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway3.4

12.1 months

Financial Health7.6

D/E 1.63 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth10.0

27 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Aptinyx Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

Cash

$44.8M

Quarterly Burn

$11.4M

Runway

12.1 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jun 2027
Today~13 mo out
Catalyst within runway

Pipeline (27 candidates)

Showing 10 of 27 candidates. Sign up for full pipeline.

·3 FDA decisions·CEO: Washington Street

Frequently asked questions

How many drug candidates are in Aptinyx Inc.'s pipeline?

Aptinyx Inc. (APTX) has 27 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Aptinyx Inc.'s lead drug candidate?

Aptinyx Inc.'s most advanced tracked candidate is abiraterone (Approved) for 1 INDICATIONS AND USAGE Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer (CRPC) Metastatic high-risk castration-sensitive prostate cancer (CSPC) Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). ( 1 ) metastatic high-risk castration-sensitive prostate cancer (C.

What is Aptinyx Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Aptinyx Inc. has approximately 12.1 months of cash runway.

Who is the CEO of Aptinyx Inc.?

Washington Street is the chief executive officer of Aptinyx Inc. (APTX).

Get the full picture on Aptinyx Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.